A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
OncoC4, Inc.
Revolution Medicines, Inc.
USWM, LLC (dba US WorldMeds)
Agenus Inc.
GlaxoSmithKline
Atavistik Bio, Inc
M.D. Anderson Cancer Center
AbbVie
University of Oklahoma
Mayo Clinic
Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
NeoTX Therapeutics Ltd.
SystImmune Inc.
Exelixis
Eli Lilly and Company
Theratechnologies
Checkpoint Therapeutics, Inc.
Carisma Therapeutics Inc
EDDC (Experimental Drug Development Centre), A*STAR Research Entities